• BioNTech SE, Munich Small Molecules
  • Am Klopferspitz 19a
  • 82152 Planegg/Martinsried
  • Germany
  • Phone: +49 (0)89/818 8802-0
  • Fax: +49 (0)89/818 8802-20
  • ed.hcetnoib@ofni
Dr. Sierk Poetting CFO & COO

Dr. Sierk Poetting
CFO & COO

About BioNTech SE

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. It is our goal to develop novel therapies for cancer and other serious diseases. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. With roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine. The team in Martinsried, which joined BioNTech in 2016, focuses on small molecules therapeutics. The product candidate BNT411, a chemically synthesized TLR7 agonist, is the first candidate being developed in Martinsried and just having entered clinical Phase 1.

What is your motivation?

We are pioneers in personalised immunotherapies, committed to revolutionising patient care. For decades, we have been combining groundbreaking immunology research with modern therapeutic platforms and bioinformatics tools to develop personalized treatments for cancer and other diseases. We believe that there is a better way to treat cancer. The interaction between cancer and the immune system is influenced by various patient-specific, tumor-specific, and environmental factors. This complex interplay affects the disease progression of each patient individually and guides the selection of the most appropriate treatment.

“We aim to discover and develop the next generation of small molecule immunomodulatory compounds to improve the standard of care. The expertise of our colleagues in Martinsried is a key element to achieve this.”

Dr. Sierk Poetting
CFO & COO

Research:  The department Munich Small Molecules (MSM) of BioNTech SE is focused on the identification, characterization and development of novel innovative small molecule compounds to be used as cancer therapeutics, especially in the field of immune oncology. Several of the drug candidates discovered in recent years have been developed through regulatory preclinics into clinical phases. MSM contains all important research units to maintain a sustainable project pipeline: computer based hit finding and lead optimization, medicinal chemistry, chem- and bioanalytics as well as formulation development. To ensure a complete characterization of drug candidates, we perform also pharmacokinetic and toxicological studies in house. Our activities are supported by a broad network of biologists and pharmacologists.

Services:  As a department of BioNTech SE, MSM offers services throughout the complete discovery process. These drug discovery services encompass all research areas from the identification of initial hits to the selection of the preclinical drug development candidate. Special expertise can be provided in the fields of computational chemistry, medicinal chemistry, analytics, pharmacology and pharmacokinetics/toxicology.